Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00317408|
Recruitment Status : Unknown
Verified September 2015 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : April 24, 2006
Last Update Posted : September 25, 2015
RATIONALE: Giving combination chemotherapy and total-body irradiation before a peripheral stem cell transplant that uses the patient's or a donor's stem cells, helps stop both the growth of cancer cells and the patient's immune system from rejecting the stem cells. When the stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving combination chemotherapy and total-body irradiation followed by a stem cell transplant may be an effective treatment for anaplastic large cell lymphoma.
PURPOSE: This clinical trial is studying how well combination chemotherapy followed by stem cell transplant works in treating young patients with progressive or relapsed anaplastic large cell lymphoma.
|Condition or disease||Intervention/treatment||Phase|
|Lymphoma||Biological: anti-thymocyte globulin Drug: busulfan Drug: carboplatin Drug: carmustine Drug: cyclosporine Drug: cytarabine Drug: dexamethasone Drug: etoposide phosphate Drug: idarubicin Drug: ifosfamide Drug: leucovorin calcium Drug: lomustine Drug: melphalan Drug: methotrexate Drug: mitoxantrone hydrochloride Drug: prednisolone Drug: thiotepa Drug: vinblastine sulfate Drug: vindesine Procedure: allogeneic hematopoietic stem cell transplantation Procedure: autologous hematopoietic stem cell transplantation Procedure: peripheral blood stem cell transplantation Radiation: total-body irradiation||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||96 participants|
|Official Title:||Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence|
|Study Start Date :||April 2004|
|Actual Primary Completion Date :||February 2014|
- Event-free survival as measured by the Kaplan-Meier method
- Proportion of patients who are treated on protocol among all patients who meet the inclusion criteria
- Overall survival
- Acute and long term toxicity
- Rate of acute and chronic graft-vs-host disease in patients with allogeneic stem cell transplantation
- Treatment related mortality
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00317408
|Study Chair:||Alfred Reiter, MD||University Hospital Erlangen|
|OverallOfficial:||Denise Williams, MD||Cambridge University Hospitals NHS Foundation Trust|